Anagrelide
Showing 26 - 35 of 35
Thrombocythemia, Myeloproliferative Disorder Trial in Cambridge (Hydroxyurea, Aspirin)
Completed
- Thrombocythemia
- Myeloproliferative Disorder
-
Cambridge, Cambs, United KingdomAddenbrooke's Hospital
Jan 17, 2017
Myeloproliferative Tumors Trial in New York (AUY922)
Terminated
- Myeloproliferative Neoplasms
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Apr 11, 2016
CML Trial in Petah tikva (Treatment modification based on molecular response at 3 months)
Unknown status
- CML
- Treatment modification based on molecular response at 3 months
-
Petah tikva, IsraelRabin Medical Center
Jan 7, 2013
Leukemia, Myelofibrosis Trial in Houston (CEP-701)
Completed
- Leukemia
- Myelofibrosis
-
Houston, TexasThe University of Texas M.D. Anderson Cancer Center
Jun 19, 2012
Essential Thrombocythaemia Trial in Worldwide (Anagrelide, Hydroxyurea)
Completed
- Essential Thrombocythaemia
- Anagrelide
- Hydroxyurea
-
Innsbruck, Tirol, Austria
- +23 more
Oct 5, 2010
Chronic Myelogenous Leukemia Trial in Worldwide (Dasatinib)
Completed
- Chronic Myelogenous Leukemia
-
Birmingham, Alabama
- +69 more
Apr 13, 2011
Chronic Myeloid Leukemia, Blast Crisis Trial in Worldwide (Dasatinib)
Completed
- Chronic Myeloid Leukemia
- Blast Crisis
-
Birmingham, Alabama
- +61 more
Aug 3, 2010
Healthy Trial in Fargo (Anagrelide Hydrochloride Capsules 1 mg, Agrylin® Capsules 1 mg)
Completed
- Healthy
- Anagrelide Hydrochloride Capsules 1 mg
- Agrylin® Capsules 1 mg
-
Fargo, North DakotaPRACS Institute, Ltd.
Mar 31, 2008
Healthy Trial in Fargo (Anagrelide Hydrochloride Capsules 1 mg, Agrylin® Capsules 1 mg)
Completed
- Healthy
- Anagrelide Hydrochloride Capsules 1 mg
- Agrylin® Capsules 1 mg
-
Fargo, North DakotaPRACS Institute, Ltd.
Mar 31, 2008